Merrimack Justifies $11,200/Month For Onivyde In Pancreatic Cancer
Launch of Onivyde (MM-398) in metastatic pancreatic cancer will be rapid; Merrimack says market research suggests payers will be on board for labeled indication.
You may also be interested in...
CEO removed as part of 22% staff cut as Merrimack looks to increase runway while awaiting data to add first-line pancreatic cancer to the Onivyde label.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.